Low Rates of Fibrosis in Eyes Treated with the Port Delivery Platform with Ranibizumab or with Monthly Ranibizumab in the Archway Trial
{{output}}
Purpose: To evaluate the proportion of eyes with fibrosis in the Archway neovascular age-related macular degeneration trial, which compared efficacy and safety between monthly injections of ranibizumab with treatment via the Port... ...
